MoneyWorks4Me

Kopran - Quaterly Results

20 May 2026 Evaluate
The Turnover for the quarter ended March 2026 of Rs. 1180.39 millions increase by 55.45% from Rs. 759.35 millions.Net Profit witnessed a 118.02% growth almost the double from Rs. 85.98 millions to Rs. 187.45  millions  of same quarter last year.Operating Profit saw a handsome growth to 275.89 millions from 142.04 millions in the quarter ended March 2026.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1180.39 759.35 55.45 3056.46 2710.10 12.78 3056.46 2710.10 12.78
Other Income 10.03 19.17 -47.68 19.99 59.04 -66.14 19.99 59.04 -66.14
PBIDT 275.89 142.04 94.23 495.75 445.60 11.25 495.75 445.60 11.25
Interest 11.72 12.58 -6.84 42.00 37.66 11.52 42.00 37.66 11.52
PBDT 264.17 129.46 104.06 453.75 407.94 11.23 453.75 407.94 11.23
Depreciation 13.44 12.39 8.47 49.81 49.99 -0.36 49.81 49.99 -0.36
PBT 250.73 117.07 114.17 403.94 357.95 12.85 403.94 357.95 12.85
TAX 63.28 31.09 103.54 99.94 89.38 11.81 99.94 89.38 11.81
Deferred Tax 5.45 3.74 45.72 9.58 3.06 213.07 9.58 3.06 213.07
PAT 187.45 85.98 118.02 304.00 268.57 13.19 304.00 268.57 13.19
Equity 482.86 482.86 0.00 482.86 482.86 0.00 482.86 482.86 0.00
PBIDTM(%) 23.37 18.71 24.95 16.22 16.44 -1.35 16.22 16.44 -1.35
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..